ImmunoGen Analysis

IMGNDelisted Stock  USD 31.23  0.01  0.03%   
ImmunoGen is overvalued with Real Value of 23.08 and Hype Value of 31.21. The main objective of ImmunoGen delisted stock analysis is to determine its intrinsic value, which is an estimate of what ImmunoGen is worth, separate from its market price. There are two main types of ImmunoGen's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect ImmunoGen's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of ImmunoGen's stock to identify patterns and trends that may indicate its future price movements.
The ImmunoGen stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ImmunoGen is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. ImmunoGen Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ImmunoGen's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

ImmunoGen Stock Analysis Notes

About 91.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.28. ImmunoGen had not issued any dividends in recent years. ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people. To learn more about ImmunoGen call Daniel Junius at 781 895 0600 or check out https://www.immunogen.com.

ImmunoGen Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ImmunoGen's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ImmunoGen or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
ImmunoGen is not yet fully synchronised with the market data
ImmunoGen has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 287.61 M. Net Loss for the year was (73.52 M) with loss before overhead, payroll, taxes, and interest of (104.76 M).
ImmunoGen currently holds about 373.87 M in cash with (197.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.69.
Over 91.0% of the company shares are owned by institutional investors

ImmunoGen Upcoming and Recent Events

Earnings reports are used by ImmunoGen to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ImmunoGen previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024
Upcoming Quarterly Report
View
26th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

ImmunoGen Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.72 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ImmunoGen's market, we take the total number of its shares issued and multiply it by ImmunoGen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

ImmunoGen Profitablity

ImmunoGen's profitability indicators refer to fundamental financial ratios that showcase ImmunoGen's ability to generate income relative to its revenue or operating costs. If, let's say, ImmunoGen is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, ImmunoGen's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of ImmunoGen's profitability requires more research than a typical breakdown of ImmunoGen's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.23 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.23.

ImmunoGen Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmunoGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmunoGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ImmunoGen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

ImmunoGen Predictive Daily Indicators

ImmunoGen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ImmunoGen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

About ImmunoGen Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how ImmunoGen prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ImmunoGen shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as ImmunoGen. By using and applying ImmunoGen Stock analysis, traders can create a robust methodology for identifying ImmunoGen entry and exit points for their positions.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding ImmunoGen to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Optimization Now

   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Module
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the ImmunoGen information on this page should be used as a complementary analysis to other ImmunoGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Consideration for investing in ImmunoGen Stock

If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Global Correlations
Find global opportunities by holding instruments from different markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon